Bioprocessing & Manufacturing Track



With new vaccine formulations and technology platforms, vaccine developers need to have the right processes in place to manufacture them during clinical trials and at commercial scale.

Use this opportunity to meet with the manufacture and bioprocessing leads who need services for all of the latest manufacturing challenges, from formulating and manufacturing adjuvants, mRNA platforms, VLPs and viral vectors, to technology transfer and continuous manufacturing.



Who Sponsors?



• CMOs
• Fill / Finish
• Finished Dosage
• Platform Technology Providers
• Big Pharma
• Biotechs

Who Attends



• Pharma
• Biotechs
• National and International Government
• Academics And Research Institutions

Job Titles



• Head of Bioprocessing
• Head of Manufacturing
• Head of Formulation
• Head of Biopharmaceutical Development
• Head of Upstream / Downstream Process
• Head of R&D
• Head of Procurement
• Head of CMC





Bioprocess, Delivery & Manufacture, Tuesday 30 October 2018

Opening Plenary Session

Dr Martin Friede

Short morning break followed by session tracks

Bioprocess, Delivery & Manufacture

Integrated Bioprocessing & Delivery

Ivo Ploemen
Bioprocess, Delivery & Manufacture

Bridging the Global Health Gap – Viral and bacterial vaccine development at Intravacc

Bioprocess, Delivery & Manufacture

Latest advancements in production process intensification to support demand for affordable vaccines

Senior representative, Batavia Biosciences
Dr Joerg (Jörg) Schwinde
Bioprocess, Delivery & Manufacture

High-density vero cell perfusion culture in packed-bed bioreactors


Morning Networking Break

Bioprocess, Delivery & Manufacture

Formulation and chromatography methods: Virus-like particle processes

Bioprocess, Delivery & Manufacture

DiViNe project - Affinity chromatography for vaccines purification

Senior representative, Affilogic
Dr Anissa Boumlic-Courtade
Bioprocess, Delivery & Manufacture

Virus safety for viral vaccines and viral vectors

Andreas Neubert
Bioprocess, Delivery & Manufacture

Development of a new manufacturing platform technology for human vaccines

Creating scale-down models that can be accurately applied to the commercial scale

Networking Lunch & Poster Session

Amelie Raveneau
Bioprocess, Delivery & Manufacture

A proven single-use platform to accelerate the development and production of viral vaccines

Dr Tarit Mukhopadhyay
Bioprocess, Delivery & Manufacture

Platform manufacturing processes - Designing vaccines for the Global Health need?

Prof Dennis Christensen
Bioprocess, Delivery & Manufacture

Targeted delivery in rational vaccine design

How physico-chemical properties of liposomes, emulsions, antigens and different routes of delivery can influence the immunological outcome
Dr Yotam Levin
Bioprocess, Delivery & Manufacture

Combining intradermal delivery and adjuvants; A new frontier in vaccine enhancement

Bioprocess, Delivery & Manufacture

Finding the missing link in complete single use fermentation line

Chair closing remarks of day one followed by Drinks Reception

last published: 12/Jul/18 18:05

Bioprocess, Delivery & Manufacture, Wednesday 31 October 2018

Bioprocess, Delivery & Manufacture

Chair’s opening remarks

Bioprocess, Delivery & Manufacture

Integrated Biomanufacturing & Supply

Dr Katherine Shives
Bioprocess, Delivery & Manufacture

Influenza A and B – Rapid and Precise Antibody-Based Quantification using Sartorius’ Virus Counter 3100

Nathalie Charland
Bioprocess, Delivery & Manufacture

The plant-based Proficia™ technology: a game changer for influenza vaccine production

Senior representative, Medicago
Bioprocess, Delivery & Manufacture

Continuous production of influenza viruses in cell culture and use of continuous downstream processing for purification of virus particles/viral antigens

Reserved for IFPMA

Morning Networking Break

Bioprocess, Delivery & Manufacture

Comparing traditional vaccine manufacturing to mRNA vaccine manufacturing

Antonio Roldao
Bioprocess, Delivery & Manufacture

Bioprocess engineering of insect cells for enhanced production of VLPs for vaccine development

Dr Dicky Abraham
Bioprocess, Delivery & Manufacture

From development to commercialization of vaccines – A case study


Afternoon Networking Lunch


Dr Giovanna Zanoni

Status of vaccine confidence around the world

  • Social and political factors that can affect uptake of vaccines
  • How can we better educate the public the benefits of immunisation?
  • How can public health institutions, government and vaccine developers help with building a coherent story
  • AEFI surveillance and risk communication
  • Are we overlooking the power of social media?
Dr Helen Bright

Flumist vaccine effectiveness – It’s return and the real story

  • Questions over the effectiveness of the live attenuated vaccine
  • Why it lost its recommendation
  • The journey, investigation and trial data to rectify this
Dr Rino Rappuoli

Chair’s closing remarks and close of congress

last published: 12/Jul/18 18:05


Sign Up for Event Updates